Changing the paradigm in conducting randomized clinical studies in advanced pancreatic cancer: an opportunity for better clinical development.

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

Who cites it

13 citing papers in PubMed.

1. Lenalidomide in combination with gemcitabine as first-line treatment for patients with metastatic carcinoma of the pancreas: a Sarah Cannon Research Institute phase II trial.Cancer biology & therapy · 2013
   Trial
2. A phase I dose-escalation study of lenalidomide in combination with gemcitabine in patients with advanced pancreatic cancer.PloS one · 2015
   Article
3. TTD consensus document on the diagnosis and management of exocrine pancreatic cancer.Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico · 2014
   Review
4. Pancreatic biomarkers: could they be the answer?World journal of gastroenterology · 2014
   Review
5. Triple approach strategy for patients with locally advanced pancreatic carcinoma.HPB : the official journal of the International Hepato Pancreato Biliary Association · 2013
   Observational
6. Pancreatic cancer: why is it so hard to treat?Therapeutic advances in gastroenterology · 2013
   Article
7. A Multi-institutional Phase 2 Study of Imatinib Mesylate and Gemcitabine for First-Line Treatment of Advanced Pancreatic Cancer.Gastrointestinal cancer research : GCR · 2012
   Article
8. PIK3CA/PTEN mutations and Akt activation as markers of sensitivity to allosteric mTOR inhibitors.Clinical cancer research : an official journal of the American Association for Cancer Research · 2012
   Article
9. Somatic variation and cancer: therapies lost in the mix.Human genetics · 2011
   Review
10. Human Equilibrative Nucleoside Transporter 1 (hENT1) in Pancreatic Adenocarcinoma: Towards Individualized Treatment Decisions.Cancers · 2010
    Article
11. Current and emerging therapies for the treatment of pancreatic cancer.OncoTargets and therapy · 2010
    Article
12. A combination of DR5 agonistic monoclonal antibody with gemcitabine targets pancreatic cancer stem cells and results in long-term disease control in human pancreatic cancer model.Molecular cancer therapeutics · 2010
    Article
13. Chemotherapy: Gemcitabine remains the standard of care for pancreatic cancer.Nature reviews. Clinical oncology · 2010
    Article

Corrections and comments

• Comment on
  Phase III randomized comparison of gemcitabine versus gemcitabine plus capecitabine in patients with advanced pancreatic cancer.2009
• Comment on
  Randomized phase II study of gemcitabine administered at a fixed dose rate or in combination with cisplatin, docetaxel, or irinotecan in patients with metastatic pancreatic cancer: CALGB 89904.2009
• Comment on
  Consensus report of the national cancer institute clinical trials planning meeting on pancreas cancer treatment.2009
• Comment on
  Dose finding and early efficacy study of gemcitabine plus capecitabine in combination with bevacizumab plus erlotinib in advanced pancreatic cancer.2009

Authors and funding

2 authors.

Funding

No grant is acknowledged in the PubMed record.

Abstract

PubMed holds no abstract for this paper.

Indexed as